News | July 04, 2023
Biocon Biologics' Hulio Biosimilar to Humira now available in the US
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
The company is already marketing the 4 mg and 10 mg strengths
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Subscribe To Our Newsletter & Stay Updated
